Skip to main content
Back to Corporate Site
Menu

Press Releases

Press release year list 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
December 09, 2019
ADC Therapeutics Announces Oral Presentation of Interim Efficacy Data from Pivotal Phase 2 Clinical Trial of ADCT-402 (Loncastuximab Tesirine) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma at 61st ASH Annual Meeting
Download PDF format download (opens in new window)
November 06, 2019
ADC Therapeutics Announces Presentations at 61st American Society of Hematology (ASH) Annual Meeting
Download PDF format download (opens in new window)
November 05, 2019
ADC Therapeutics Appoints Jennifer Herron as Chief Commercial Officer
Download PDF format download (opens in new window)
November 04, 2019
ADC Therapeutics Announces Publication of ADCT-402 Data in Clinical Cancer Research
Download PDF format download (opens in new window)
October 17, 2019
ADC Therapeutics Doses First Patients in Pivotal Phase 2 Clinical Trial of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma
Download PDF format download (opens in new window)
October 02, 2019
ADC Therapeutics Announces Withdrawal of Registration Statement
Download PDF format download (opens in new window)
September 23, 2019
ADC Therapeutics Announces Launch of Initial Public Offering
Download PDF format download (opens in new window)
September 06, 2019
ADC Therapeutics Files Registration Statement for Proposed Initial Public Offering
Download PDF format download (opens in new window)
August 26, 2019
ADC Therapeutics and Freenome Enter Biomarker Development Collaboration
Download PDF format download (opens in new window)
August 06, 2019
ADC Therapeutics and SOPHiA GENETICS Partner for Biomarker Discovery in Pivotal Phase II Clinical Trial
Download PDF format download (opens in new window)
July 09, 2019
ADC Therapeutics Announces Final Close of Series E Financing Expansion
Download PDF format download (opens in new window)
June 21, 2019
ADC Therapeutics Presents Clinical Data on ADCT-402 and ADCT-301 in Subtypes of Relapsed or Refractory Lymphoma at the 15th International Conference on Malignant Lymphoma
Download PDF format download (opens in new window)
June 12, 2019
ADC Therapeutics Announces Completion of a Series E Financing Expansion
Download PDF format download (opens in new window)
June 12, 2019
ADC Therapeutics Announces Presentations at the 15th International Conference on Malignant Lymphoma
Download PDF format download (opens in new window)
April 24, 2019
ADC Therapeutics and Adagene Announce License Agreement
Download PDF format download (opens in new window)
February 20, 2019
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
Download PDF format download (opens in new window)
February 13, 2019
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and IMFINZI® (durvalumab) in Multiple Types of Advanced Non-Hodgkin Lymphoma
Download PDF format download (opens in new window)
January 16, 2019
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors
Download PDF format download (opens in new window)
January 04, 2019
ADC Therapeutics Doses First Patient in Phase Ib Clinical Trial of ADCT-301 in Patients with Advanced Solid Tumors
Download PDF format download (opens in new window)
January 03, 2019
ADC Therapeutics to Appoint Peter Hug, Ph.D., to Board of Directors
Download PDF format download (opens in new window)